Therefore, the UK Cancer Genetics Group (UKCGG), with support from the George Pantziarka TP53 Trust (the UK LFS patient advocacy group), organised a national consensus meeting on 6 July 2018 to agree on a consistent approach to the management of TP53 carriers across the UK. The gene discussed is TP53; the disease is cancer.